UK MHRA Says Genetic Biobank Could Transform Drug Safety Monitoring Through Personalized Medicine
The biobank, which the UK regulator believes puts it at the forefront of innovation in the field of drug safety monitoring, will enter a pilot in June, starting with the gout treatment allopurinol and related rare, severe skin reactions.
You may also be interested in...
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
Applications from drug companies should also include a commercial proposal, says Pharmac.